-
-
- 2021-06-28
Fosun Pharma: Second-generation TRK Inhibitor FCN-098 Clinically Approved
Recently, the Investigational New Drug Application (IND) was approved for FCN-098 capsules, a Class 1 new drug independently developed by Chongqing Fochon Pharmaceutical Research Co., Ltd. (hereinafter referred to as "Fochon Pharmaceuticals"). As a second-generation TRK inhibitor, FCN-098 is intended for the treatment of patients with advanced solid tumors with NTRK gene mutation.
-
-
-
- 2021-06-24
Fosun Pharma: Metronidazole Tablets of Guilin Pharma, Subsidiary of Fosun Pharma, Passes Generics Consistency Evaluation
On June 17, Guilin Pharmaceutical Co., Ltd. received the Approval Letter of Supplementary Application of metronidazole tablets issued by the National Medical Products Administration (NMPA): the drug passed generics consistency evaluation. Allegedly, metronidazole tablets manufactured by only 7 pharmaceutical companies in China, including Guilin Pharma, have passed the consistency evaluation.
-
-
-
- 2021-06-23
Fosun Kite's First CAR-T Product Yescarta® (Axicabtagene Ciloleucel) Approved for Marketing
Axicabtagene Ciloleucel (FKC876) is an autologous CD19-directed CAR-T cell therapy manufactured in China pursuant to a license from Kite, a Gilead Company ("Kite") of Kite's Yescarta (axicabtagene ciloleucel)
-
-
-
- 2021-06-11
Fosun Kite's FKC-876 Granted Approval for New Indication in Clinics
[Shanghai, China] Fosun Kite Biotechnology Co., Ltd. announced today that the National Medical Products Administration (NMPA) has officially approved the IND application [Acceptance No.CXSL2100098] for the registration of a new indication of Axicabtagene Ciloleucel (FKC876), a CD19-targeted autologous CAR-T cell therapy product of Fosun Kite for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma (r/r iNHL) after two or more lines of systemic therapy.
-
-
-
- 2021-06-02
Fosun Pharma: Loratadine Tablets Passes Generics Consistency Evaluation
Recently, Jiangsu Huanghe Pharmaceutical Co., Ltd., a member enterprise of Wanbang Biopharma under Fosun Pharma, received the Notice on Approval of Supplementary Drug Application for Loratadine Tablets (10 mg) from NMPA because the drug has passed the consistency evaluation of quality and efficacy of generic drugs.
-
-
-
- 2021-06-01
Fosun Pharma's Independently Developed Small Molecule Innovator DrugFCN-159 Tablet Approved by FDA for Clinical Trials
[June 1, 2021, Shanghai, China] Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; Stock Code: 600196.SH; 02196.HK) issued an announcement that its holding subsidiary Shanghai Fosun Pharmaceutical Development Co., Ltd. (hereinafter referred to as"Fosun Pharma Development") recently received a notice from the US FDA (Food and Drug Administration) regarding the approval of its FCN-159 tablets (hereinafter referred to as"the new drug") for the treatment of neurofibromatosis type I (NF1) in adults and children for clinical trials. Fosun Pharma plans to conduct clinical trials of this new drug for this approved indication in the United States after the conditions are available.
-
-
-
- 2021-04-23
Fosun Pharma: The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab Accepted by NMPA and Granted Priority Review
Shanghai, China, April 22th, 2021 –Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors that fail to respond to the standard therapy, has been accepted by the National Medical Products Administration (NMPA) and proposed to be granted priority review. Serplulimab is potentially to be the first anti-PD-1 mAb in MSI-H solid tumors in China. For this indication, patients are screened for specific MSI-H tumor markers, rather than classifying the tumor types, covering a wide range of cancer types. Henlius adopts the “Combo+Global” development strategy for serplulimab, focusing on indication differentiation and combination therapy, with a total of 10 clinical trials conducted worldwide.
-
-
-
- 2021-04-21
Third Clinical Trial Approval outside of China Received — EU Application for Clinical Trial of Henlius Bevacizumab HLX04-O Approved for Ophthalmologic Indication
In October 2020, Henlius entered into a co-development and exclusive license agreement with Essex. With this collaboration, Henlius and Essex plan to conduct global multi-centre clinical trials of HLX04 in China, Australia, the European Union and the United States, and apply marketing authorization in different countries and regions around the globe based on the research results.
-
-
-
- 2021-04-16
Henlius New Immune Checkpoint Inhibitor — Henlius Receives IND Approval from NMPA for Novel Anti-LAG-3 mAb
Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor and is regarded as a new generation of immunotherapy target after PD-1/L1 and CTLA-4. Currently, there is no LAG-3 targeted product on the market around the globe.
-